Older patients in hospitals across China took part in a major multi-centre open-label randomised clinical trial that showed there was no difference in post-operative delirium in older people with a hip fracture.
Adam Cunningham, Professor of Functional Immunity, speculates on how might the Omicron variant might affect future COVID-19 variants.
A University of Birmingham-led study shows an increased risk of patients developing illnesses including mental ill-health and heart conditions if they have a GP-inputted medical history of gum disease.
The University of Birmingham today announces the launch of five new major studies aimed at improving the prevention, treatment and management of type 1 diabetes – with a particular focus on children and young adults.
A proof-of-concept trial has identified a drug that may offer benefit some patients hospitalised with COVID-19 pneumonia.
An additional 100,000 elective operations could be cancelled in England this winter as a result of the Omicron wave leading to increased hospital admissions.
A new clinical trial being led by the University of Birmingham and funded by the British Heart Foundation could help improve the recovery of children who undergo life-saving heart surgery.
Elderly care home residents who have previously contracted and survived COVID-19 develop much stronger and higher antibody and cellular immune responses to two doses of vaccination, research finds.
CARE Fertility has generously donated £202,800 to support the miscarriage research led by Professor Arri Coomarasamy and team at the University of Birmingham.
A UK-wide trial carried out in collaboration with the University of Birmingham show six COVID-19 vaccines are safe and boost immunity for people who have had two doses of Pfizer/BioNTech or Oxford/AstraZeneca.
The University of Birmingham and Huazhong University of Science and Technology (HUST) have signed a 'Key Partner' agreement that paves the way for a growth in their collaborations in both teaching and research.
LifeArc and PSC Support jointly award £898,774 for new research into primary sclerosing cholangitis (PSC), a rare disease where the body attacks its own liver, causing inflammation and scarring of the bile ducts.